8-K Announcements
6Material company update
Nov 19, 2025·SEC
Material company update
Nov 12, 2025·SEC
Material company update
Aug 8, 2025·SEC
Surmodics, Inc.(SRDX)Earnings, Financials & Key Ratios
SRDX•NASDAQ
Price updated Apr 30, 2026
AboutSurmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.Show more
- Revenue$126M-4.9%
- EBITDA$3M-78.7%
- Net Income-$12M-651.4%
- EPS (Diluted)-0.82-645.5%
- Gross Margin73.81%+60.4%
- EBITDA Margin2.42%-77.6%
- Operating Margin-4.48%-215.3%
- Net Margin-9.15%-690.2%
- ROE-9.67%-618.4%
SRDX Key Insights
Surmodics, Inc. (SRDX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 89 (top 11%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SRDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SRDX Price & Volume
Surmodics, Inc. (SRDX) stock price & volume — 10-year historical chart
Loading chart...
SRDX Growth Metrics
Surmodics, Inc. (SRDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.18%
5 Years4.73%
3 Years6.24%
TTM-0.02%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1159.97%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1151.27%
Return on Capital
10 Years2.68%
5 Years-2.35%
3 Years-5.05%
Last Year-3.53%
SRDX Recent Earnings
Surmodics, Inc. (SRDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 8/12 qtrs (67%)
Q3 2025Latest
Aug 8, 2025Metric
Actual
Est
EPS
$0.06+128.6%
$0.21
Rev
$30M-1.4%
$30M
Q2 2025
Apr 30, 2025Metric
Actual
Est
EPS
$0.13-116.7%
$0.06
Rev
$28M-12.9%
$32M
Q1 2025
Jan 30, 2025Metric
Actual
Est
EPS
$0.04+66.7%
$0.12
Rev
$30M-10.3%
$33M
Q4 2024
Nov 6, 2024Metric
Actual
Est
EPS
$0.13+51.9%
$0.27
Rev
$33M+9.3%
$30M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2025Latest | Aug 8, 2025 | $0.06vs $0.21+128.6% | $30Mvs $30M-1.4% |
| Q2 2025 | Apr 30, 2025 | $0.13vs $0.06-116.7% | $28Mvs $32M-12.9% |
| Q1 2025 | Jan 30, 2025 | $0.04vs $0.12+66.7% | $30Mvs $33M-10.3% |
| Q4 2024 | Nov 6, 2024 | $0.13vs $0.27+51.9% | $33Mvs $30M+9.3% |
Based on last 12 quarters of dataView full earnings history →
SRDX Peer Comparison
Surmodics, Inc. (SRDX) competitors in Device suppliers, distribution, and services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 | |
 ANGO | 505.13M | 12.15 | -14.64 | -3.76% | -9.02% | -15.71% | ||
 LAKE | 99.48M | 10.08 | -3.83 | 15.21% | -10.88% | -15.54% | 0.37 | |
 MMSI | 4.01B | 67.22 | 31.56 | 11.66% | 9.03% | 8.95% | 0.57 | |
 ITGR | 3.13B | 90.96 | 31.47 | 7.57% | 7.67% | 8.23% | 0.80 | |
 PCVX | 7.43B | 51.44 | -9.14 | -32.51% | 0.09 | |||
 CNMD | 1B | 32.58 | 21.58 | 5.16% | 4% | 5.4% | 0.81 |
Compare SRDX vs Peers
Surmodics, Inc. (SRDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SRDX Income Statement
Surmodics, Inc. (SRDX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Sep'16 | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 71.37M | 73.11M | 81.34M | 100.08M | 94.86M | 105.14M | 99.95M | 132.58M | 126.08M | 120.8M |
Revenue Growth % | 15.3% | 2.45% | 11.25% | 23.04% | -5.21% | 10.83% | -4.93% | 32.65% | -4.91% | -0.02% |
Cost of Goods Sold | 29.41M | 43.24M | 54.97M | 66.52M | 65.5M | 63.91M | 70.95M | 71.56M | 33.03M | 32.51M |
COGS % of Revenue | 41.2% | 59.14% | 67.58% | 66.47% | 69.05% | 60.79% | 70.99% | 53.97% | 26.19% | - |
Gross Profit | 41.96M▲ 0% | 29.87M▼ 28.8% | 26.37M▼ 11.7% | 33.55M▲ 27.3% | 29.36M▼ 12.5% | 41.23M▲ 40.4% | 29M▼ 29.7% | 61.02M▲ 110.4% | 93.05M▲ 52.5% | 88.3M▲ 0% |
Gross Margin % | 58.8% | 40.86% | 32.42% | 33.53% | 30.95% | 39.21% | 29.01% | 46.03% | 73.81% | 73.09% |
Gross Profit Growth % | 13.06% | -28.81% | -11.74% | 27.26% | -12.5% | 40.42% | -29.65% | 110.43% | 52.48% | - |
Operating Expenses | 20.42M | 22.9M | 26.6M | 26.36M | 30.61M | 80.76M | 51.1M | 102.47M | 98.7M | 100.64M |
OpEx % of Revenue | 28.62% | 31.32% | 32.71% | 26.33% | 32.27% | 76.81% | 51.12% | 77.29% | 78.28% | - |
Selling, General & Admin | 18M | 20.48M | 24.11M | 23.95M | 28.39M | 30.68M | 46.95M | 51.88M | 56.84M | 62.55M |
SG&A % of Revenue | 25.22% | 28.01% | 29.64% | 23.93% | 29.93% | 29.18% | 46.97% | 39.13% | 45.08% | - |
Research & Development | 18.5M | 31.82M | 40.97M | 52.88M | 50.19M | 46.73M | 9.08M | 9.57M | 10M | 11.76M |
R&D % of Revenue | 25.92% | 43.52% | 50.38% | 52.84% | 52.91% | 44.45% | 9.09% | 7.22% | 7.93% | - |
Other Operating Expenses | 89K | -70K | 1.27M | -50.48M | -47.97M | 3.34M | -4.93M | 41.01M | 31.86M | 4M |
Operating Income | 16.86M▲ 0% | 7.1M▼ 57.9% | -8.8M▼ 223.9% | 6.47M▲ 173.5% | -1.25M▼ 119.3% | 6.7M▲ 635.8% | -22.1M▼ 429.7% | 5.15M▲ 123.3% | -5.64M▼ 209.6% | -12.35M▲ 0% |
Operating Margin % | 23.62% | 9.72% | -10.82% | 6.46% | -1.32% | 6.38% | -22.11% | 3.88% | -4.48% | -10.22% |
Operating Income Growth % | -11.68% | -57.87% | -223.88% | 173.52% | -119.34% | 635.81% | -429.66% | 123.31% | -209.61% | - |
EBITDA | 21.73M | 12.66M | -2.37M | 13.78M | 6.01M | 14.72M | -12.43M | 14.32M | 3.05M | -4.49M |
EBITDA Margin % | 30.45% | 17.31% | -2.91% | 13.77% | 6.34% | 14% | -12.43% | 10.8% | 2.42% | -3.72% |
EBITDA Growth % | -0.74% | -41.75% | -118.71% | 681.97% | -56.37% | 144.84% | -184.42% | 215.27% | -78.71% | -384.43% |
D&A (Non-Cash Add-back) | 4.87M | 5.55M | 6.43M | 7.31M | 7.26M | 8.02M | 9.67M | 9.17M | 8.69M | 7.85M |
EBIT | 21.54M | 7.38M | -7.53M | 6.86M | -1.32M | 6.66M | -21.89M | 5.98M | -3.97M | -13.8M |
Net Interest Income | 0 | 0 | 0 | -152K | -133K | -310K | -598K | -3.49M | -3.54M | -2.97M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 518K |
Interest Expense | 0 | 0 | 0 | 152K | 133K | 310K | 598K | 3.49M | 3.54M | 3.49M |
Other Income/Expense | 89K | -70K | 1.27M | 1.09M | -203K | -357K | -396K | -2.66M | -1.86M | -2.35M |
Pretax Income | 16.95M▲ 0% | 7.03M▼ 58.5% | -7.53M▼ 207.1% | 7.56M▲ 200.3% | -1.45M▼ 119.2% | 6.35M▲ 536.5% | -22.49M▼ 454.4% | 2.49M▲ 111.1% | -7.51M▼ 401.8% | -14.69M▲ 0% |
Pretax Margin % | 23.75% | 9.62% | -9.26% | 7.55% | -1.53% | 6.04% | -22.5% | 1.88% | -5.95% | -12.16% |
Income Tax | 6.96M | 3.11M | -3.08M | -34K | -2.58M | 2.11M | 4.78M | 4.02M | 4.04M | 2.94M |
Effective Tax Rate % | 41.08% | 44.18% | 40.83% | -0.45% | 177.24% | 33.23% | -21.26% | 161.76% | -53.77% | -19.98% |
Net Income | 9.98M▲ 0% | 3.93M▼ 60.7% | -4.46M▼ 213.5% | 7.59M▲ 270.3% | 1.12M▼ 85.2% | 4.24M▲ 277.3% | -27.27M▼ 743.7% | -1.54M▲ 94.4% | -11.54M▼ 651.4% | -17.63M▲ 0% |
Net Margin % | 13.99% | 5.37% | -5.48% | 7.59% | 1.18% | 4.03% | -27.29% | -1.16% | -9.15% | -14.59% |
Net Income Growth % | -25.75% | -60.68% | -213.53% | 270.34% | -85.21% | 277.29% | -743.71% | 94.37% | -651.43% | -1159.97% |
Net Income (Continuing) | 9.98M | 3.93M | -4.46M | 7.59M | 1.12M | 4.24M | -27.27M | -1.54M | -11.54M | -17.63M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.76▲ 0% | 0.29▼ 61.8% | -0.34▼ 217.2% | 0.55▲ 261.8% | 0.08▼ 85.2% | 0.30▲ 269.0% | -1.96▼ 753.3% | -0.11▲ 94.4% | -0.82▼ 645.5% | -1.23▲ 0% |
EPS Growth % | -24.75% | -61.84% | -217.24% | 261.76% | -85.22% | 269% | -753.33% | 94.39% | -645.45% | -1151.27% |
EPS (Basic) | 0.77 | 0.30 | -0.34 | 0.57 | 0.08 | 0.31 | -1.96 | -0.11 | -0.82 | - |
Diluted Shares Outstanding | 13.22M | 13.39M | 13.16M | 13.78M | 13.81M | 13.99M | 13.92M | 14.03M | 14.15M | 14.28M |
Basic Shares Outstanding | 13M | 13.15M | 13.11M | 13.39M | 13.55M | 13.77M | 13.92M | 14.03M | 14.15M | 14.28M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SRDX Balance Sheet
Surmodics, Inc. (SRDX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Sep'16 | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 58.56M | 60.88M | 81.53M | 81.42M | 86.61M | 70.25M | 57.59M | 86.69M | 81.3M | 75.99M |
Cash & Short-Term Investments | 46.94M | 48.34M | 64.67M | 55.29M | 61.1M | 38.87M | 19M | 45.35M | 40.11M | 32.73M |
Cash Only | 24.99M | 16.53M | 23.32M | 30.36M | 30.79M | 31.15M | 19M | 41.42M | 36.12M | 26.28M |
Short-Term Investments | 21.95M | 31.8M | 41.35M | 24.93M | 30.31M | 7.72M | 0 | 3.93M | 4M | 6.45M |
Accounts Receivable | 7.57M | 7.81M | 8.88M | 17.76M | 16.17M | 22.91M | 24.2M | 23.9M | 23.27M | 25.02M |
Days Sales Outstanding | 38.7 | 38.99 | 39.84 | 64.78 | 62.23 | 79.55 | 88.37 | 65.8 | 67.37 | 69.58 |
Inventory | 3.58M | 3.52M | 4.02M | 4.5M | 5.97M | 6.76M | 11.82M | 14.84M | 15.17M | 15.76M |
Days Inventory Outstanding | 44.42 | 29.68 | 26.67 | 24.7 | 33.24 | 38.61 | 60.8 | 75.69 | 167.64 | 174.74 |
Other Current Assets | 697K | 599K | 1.5M | 0 | 1.95M | 0 | 0 | 0 | 0 | 2.49M |
Total Non-Current Assets | 74.34M | 75.71M | 82.61M | 78.44M | 82.16M | 124.34M | 100.77M | 99.04M | 97.26M | 93.83M |
Property, Plant & Equipment | 19.6M | 22.94M | 30.14M | 29.75M | 30.1M | 30.09M | 27.15M | 26.03M | 27.98M | 22.84M |
Fixed Asset Turnover | 3.64x | 3.19x | 2.70x | 3.36x | 3.15x | 3.49x | 3.68x | 5.09x | 4.51x | 4.81x |
Goodwill | 26.55M | 27.28M | 27.03M | 26.17M | 27.18M | 45.61M | 40.71M | 42.95M | 44.64M | 46.32M |
Intangible Assets | 22.52M | 20.56M | 17.68M | 14.23M | 13.28M | 37.05M | 28.14M | 26.21M | 23.57M | 21.62M |
Long-Term Investments | 479K | 479K | 479K | 479K | 0 | 2M | 0 | 0 | 0 | 1.04M |
Other Non-Current Assets | 149K | 418K | 967K | 1.65M | 4.27M | 3.72M | 4.77M | 1.86M | 1.06M | 2.81M |
Total Assets | 132.89M▲ 0% | 136.59M▲ 2.8% | 164.13M▲ 20.2% | 159.87M▼ 2.6% | 168.76M▲ 5.6% | 194.59M▲ 15.3% | 158.36M▼ 18.6% | 185.73M▲ 17.3% | 178.56M▼ 3.9% | 169.82M▲ 0% |
Asset Turnover | 0.54x | 0.54x | 0.50x | 0.63x | 0.56x | 0.54x | 0.63x | 0.71x | 0.71x | 0.72x |
Asset Growth % | 32.62% | 2.78% | 20.16% | -2.6% | 5.57% | 15.3% | -18.62% | 17.29% | -3.86% | -28.01% |
Total Current Liabilities | 10.13M | 9.8M | 35.13M | 20.21M | 18.89M | 29.82M | 32.08M | 23.95M | 20.54M | 19.44M |
Accounts Payable | 1.62M | 2.4M | 2.55M | 2.08M | 1.51M | 1.78M | 3.14M | 2.99M | 2.79M | 5.93M |
Days Payables Outstanding | 20.13 | 20.23 | 16.91 | 11.44 | 8.44 | 10.18 | 16.13 | 15.27 | 30.79 | 41.16 |
Short-Term Debt | 0 | 0 | 0 | 0 | 436K | 10M | 10M | 0 | 0 | 1.02M |
Deferred Revenue (Current) | 180K | 62K | 9.65M | 5.55M | 5.2M | 4.65M | 4.16M | 4.38M | 1.62M | 3.07M |
Other Current Liabilities | 2.92M | 3.52M | 17.31M | 7.99M | 4.67M | 4.39M | 4.89M | 5.57M | 13.85M | 4.21M |
Current Ratio | 5.78x | 6.21x | 2.32x | 4.03x | 4.58x | 2.36x | 1.80x | 3.62x | 3.96x | 3.91x |
Quick Ratio | 5.42x | 5.85x | 2.21x | 3.81x | 4.27x | 2.13x | 1.43x | 3.00x | 3.22x | 3.10x |
Cash Conversion Cycle | 62.99 | 48.44 | 49.6 | 78.03 | 87.03 | 107.97 | 133.04 | 126.22 | 204.22 | 203.16 |
Total Non-Current Liabilities | 15.93M | 15.23M | 20.39M | 17.14M | 18.82M | 24.69M | 17.89M | 41.87M | 39.12M | 39.07M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29.41M | 29.55M | 29.67M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 3.34M | 3.19M | 3.84M | 2.97M | 2.65M | 9.07M |
Deferred Tax Liabilities | 0 | 0 | 1.56M | 0 | 2.87M | 2.74M | 2.03M | 2M | 1.78M | 10.09M |
Other Non-Current Liabilities | 15.74M | 15.23M | 9.14M | 5.51M | 1.81M | 8.46M | 6.93M | 5.09M | 1.96M | 728K |
Total Liabilities | 26.06M | 25.04M | 55.52M | 37.35M | 37.71M | 54.51M | 49.97M | 65.82M | 59.66M | 58.51M |
Total Debt | 0 | 0 | 0 | 0 | 3.78M | 13.71M | 14.81M | 33.25M | 33.24M | 32.58M |
Net Debt | -24.99M | -16.53M | -23.32M | -30.36M | -30.35M | -17.45M | -4.19M | -12.01M | -2.87M | -26.28M |
Debt / Equity | - | - | - | - | 0.03x | 0.10x | 0.14x | 0.28x | 0.28x | 0.29x |
Debt / EBITDA | - | - | - | - | 0.63x | 0.93x | - | 2.32x | 10.90x | -7.25x |
Net Debt / EBITDA | -1.15x | -1.31x | - | -2.20x | -5.05x | -1.19x | - | -0.84x | -0.94x | 5.85x |
Interest Coverage | - | - | - | 45.11x | -9.93x | 21.47x | -36.61x | 1.71x | -1.12x | -3.96x |
Total Equity | 106.83M▲ 0% | 111.56M▲ 4.4% | 108.61M▼ 2.6% | 122.52M▲ 12.8% | 131.06M▲ 7.0% | 140.09M▲ 6.9% | 108.39M▼ 22.6% | 119.91M▲ 10.6% | 118.9M▼ 0.8% | 111.31M▲ 0% |
Equity Growth % | 14.42% | 4.42% | -2.64% | 12.8% | 6.97% | 6.89% | -22.62% | 10.63% | -0.84% | -26.18% |
Book Value per Share | 8.08 | 8.33 | 8.25 | 8.89 | 9.49 | 10.01 | 7.79 | 8.55 | 8.40 | 7.79 |
Total Shareholders' Equity | 106.83M | 111.56M | 108.61M | 122.52M | 131.06M | 140.09M | 108.39M | 119.91M | 118.9M | 111.31M |
Common Stock | 660K | 655K | 670K | 675K | 684K | 695K | 701K | 708K | 716K | 715K |
Retained Earnings | 98.15M | 102.07M | 97.61M | 110.7M | 111.83M | 116.06M | 88.79M | 87.25M | 75.71M | 61.53M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 1.27M | 3.42M | 2.72M | 396K | 3.17M | 1.73M | -9.87M | -4.76M | -2.13M | 1.2M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SRDX Cash Flow Statement
Surmodics, Inc. (SRDX) cash flow — operating, investing & free cash flow history
| Metric | Sep'16 | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 25.17M | 14.05M | 34.05M | 8.04M | 14.01M | 15.39M | -17.22M | 10.51M | 248K | -1.88M |
Operating CF Margin % | 35.26% | 19.22% | 41.87% | 8.03% | 14.77% | 14.64% | -17.23% | 7.93% | 0.2% | - |
Operating CF Growth % | 67.54% | -44.16% | 142.31% | -76.39% | 74.3% | 9.84% | -211.92% | 161.05% | -97.64% | 284.76% |
Net Income | 9.98M | 3.93M | -4.46M | 7.59M | 1.12M | 4.24M | -27.27M | -1.54M | -11.54M | -17.63M |
Depreciation & Amortization | 4.87M | 5.55M | 6.43M | 7.31M | 7.26M | 8.02M | 9.14M | 8.52M | 8.69M | 8.46M |
Stock-Based Compensation | 3.84M | 3.47M | 4.81M | 5.08M | 5.45M | 5.86M | 7.06M | 7.61M | 8.22M | 6.53M |
Deferred Taxes | 261K | 1M | -2.28M | -1.09M | -1.14M | 1.65M | 5.27M | -181K | -320K | -179K |
Other Non-Cash Items | 1.37M | 945K | 8.37M | -909K | 195K | 478K | 860K | 340K | 558K | 1.02M |
Working Capital Changes | 4.83M | -845K | 21.18M | -9.95M | 1.11M | -4.86M | -12.28M | -4.24M | -5.36M | -86K |
Change in Receivables | 911K | -528K | -1.77M | -1.63M | 3.46M | -3.46M | -1.52M | -977K | -5.24M | 1.23M |
Change in Inventory | -143K | 97K | -513K | -543K | -1.38M | -818K | -5.06M | -3.02M | -328K | -350K |
Change in Payables | 3.71M | 368K | 5.24M | -765K | -483K | 264K | 1.61M | -183K | -232K | 2.68M |
Cash from Investing | -55.47M | -16.19M | -23.5M | 9.75M | -9.07M | -25.24M | 6.23M | -6.82M | -2.94M | 5.94M |
Capital Expenditures | -8.19M | -6.43M | -14.09M | -6.75M | -3.67M | -6.28M | -3.37M | -2.92M | -3.49M | -1.66M |
CapEx % of Revenue | 11.48% | 8.8% | 17.33% | 6.74% | 3.87% | 5.97% | 3.37% | 2.2% | 2.77% | 1.38% |
Acquisitions | -25.86M | 0 | 5M | 750K | 9.07M | -39.55M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 89K | -9.76M | -5M | -740K | -9.07M | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | -199K | -6.51M | -3.39M | -11.03M | -4.65M | 10.23M | -375K | 18.41M | -2.95M | -2.75M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 10M | 0 | 19.66M | 0 | 0 |
Equity Issued (Net) | 106K | -6.41M | 2.09M | 723K | 1.61M | 3.13M | 1.25M | 1.25M | 1.22M | 721K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -388K | -6.86M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -305K | -96K | -5.48M | -11.75M | -6.26M | -2.9M | -1.62M | -2.51M | -4.17M | -3.47M |
Net Change in Cash | -30.6M▲ 0% | -8.45M▲ 72.4% | 7.13M▲ 184.4% | 6.69M▼ 6.2% | 424K▼ 93.7% | 368K▼ 13.2% | -12.15M▼ 3403.0% | 22.42M▲ 284.5% | -5.3M▼ 123.7% | 1.98M▲ 0% |
Free Cash Flow | 16.97M▲ 0% | 7.62M▼ 55.1% | 19.96M▲ 161.9% | 1.29M▼ 93.5% | 10.34M▲ 701.5% | 9.11M▼ 11.9% | -20.59M▼ 326.0% | 7.6M▲ 136.9% | -3.24M▼ 142.7% | -3.55M▲ 0% |
FCF Margin % | 23.78% | 10.42% | 24.54% | 1.29% | 10.9% | 8.67% | -20.6% | 5.73% | -2.57% | -2.94% |
FCF Growth % | 29.14% | -55.1% | 161.91% | -93.54% | 701.47% | -11.89% | -326.05% | 136.89% | -142.71% | 39.47% |
FCF per Share | 1.28 | 0.57 | 1.52 | 0.09 | 0.75 | 0.65 | -1.48 | 0.54 | -0.23 | -0.25 |
FCF Conversion (FCF/Net Income) | 2.52x | 3.58x | -7.64x | 1.06x | 12.48x | 3.63x | 0.63x | -6.85x | -0.02x | 0.20x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 74K | 415K | 2.92M | 3.04M | 1.44M |
Taxes Paid | 6.71M | 2.11M | 914K | 193K | 30K | 160K | 416K | 2.85M | 2.57M | 652K |
SRDX Key Ratios
Surmodics, Inc. (SRDX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 9.97% | 3.6% | -4.05% | 6.57% | 0.89% | 3.13% | -21.95% | -1.35% | -9.67% | -15.59% |
Return on Invested Capital (ROIC) | 21.14% | 6.02% | -7.32% | 5.47% | -0.96% | 4.44% | -14.61% | 3.58% | -3.72% | -8.01% |
Gross Margin | 58.8% | 40.86% | 32.42% | 33.53% | 30.95% | 39.21% | 29.01% | 46.03% | 73.81% | 73.09% |
Net Margin | 13.99% | 5.37% | -5.48% | 7.59% | 1.18% | 4.03% | -27.29% | -1.16% | -9.15% | -14.59% |
Debt / Equity | - | - | - | - | 0.03x | 0.10x | 0.14x | 0.28x | 0.28x | 0.29x |
Interest Coverage | - | - | - | 45.11x | -9.93x | 21.47x | -36.61x | 1.71x | -1.12x | -3.96x |
FCF Conversion | 2.52x | 3.58x | -7.64x | 1.06x | 12.48x | 3.63x | 0.63x | -6.85x | -0.02x | 0.20x |
Revenue Growth | 15.3% | 2.45% | 11.25% | 23.04% | -5.21% | 10.83% | -4.93% | 32.65% | -4.91% | -0.02% |
Related:SRDX Dividend History·SRDX Revenue History·SRDX Price History·SRDX P/E History·SRDX Financial Ratios·SRDX Institutional Holders
SRDX SEC Filings & Documents
Surmodics, Inc. (SRDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
SRDX Frequently Asked Questions
Surmodics, Inc. (SRDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Surmodics, Inc. (SRDX) reported $120.8M in revenue for fiscal year 2024. This represents a 1133% increase from $9.8M in 1998.
Surmodics, Inc. (SRDX) saw revenue decline by 4.9% over the past year.
Surmodics, Inc. (SRDX) reported a net loss of $17.6M for fiscal year 2024.
Dividend & Returns
Surmodics, Inc. (SRDX) has a return on equity (ROE) of -9.7%. Negative ROE indicates the company is unprofitable.
Surmodics, Inc. (SRDX) had negative free cash flow of $3.5M in fiscal year 2024, likely due to heavy capital investments.